SE523043C2 - Humant intestinalt Npt2B - Google Patents

Humant intestinalt Npt2B

Info

Publication number
SE523043C2
SE523043C2 SE0000375A SE0000375A SE523043C2 SE 523043 C2 SE523043 C2 SE 523043C2 SE 0000375 A SE0000375 A SE 0000375A SE 0000375 A SE0000375 A SE 0000375A SE 523043 C2 SE523043 C2 SE 523043C2
Authority
SE
Sweden
Prior art keywords
npt2b
nucleic acid
protein
sequence
expression
Prior art date
Application number
SE0000375A
Other languages
English (en)
Swedish (sv)
Other versions
SE0000375L (sv
SE0000375D0 (sv
Inventor
Paul David Cannon
Suryanarayana Sankurati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE0000375D0 publication Critical patent/SE0000375D0/xx
Publication of SE0000375L publication Critical patent/SE0000375L/
Publication of SE523043C2 publication Critical patent/SE523043C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE0000375A 1999-02-09 2000-02-07 Humant intestinalt Npt2B SE523043C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11932199P 1999-02-09 1999-02-09

Publications (3)

Publication Number Publication Date
SE0000375D0 SE0000375D0 (sv) 2000-02-07
SE0000375L SE0000375L (sv) 2000-08-10
SE523043C2 true SE523043C2 (sv) 2004-03-23

Family

ID=22383760

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000375A SE523043C2 (sv) 1999-02-09 2000-02-07 Humant intestinalt Npt2B

Country Status (14)

Country Link
US (3) US6380374B1 (de)
JP (2) JP2000245488A (de)
AT (1) AT411759B (de)
AU (1) AU741170B2 (de)
BE (1) BE1014389A5 (de)
CA (1) CA2296178C (de)
CH (1) CH694588A5 (de)
DE (1) DE10004815B4 (de)
FR (1) FR2791348B1 (de)
GB (1) GB2348645A (de)
IE (1) IE20000117A1 (de)
IT (1) ITMI20000200A1 (de)
NL (1) NL1014331C2 (de)
SE (1) SE523043C2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2000545B1 (de) * 2001-06-20 2011-08-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Lungentumoren
EP2351765A3 (de) 2001-07-10 2012-02-22 Lakewood-Amedex, Inc Oligonukleotidhaltige pharmakologische zusammensetzungen und deren verwendung
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
ES2573636T3 (es) * 2006-10-25 2016-06-09 Wisconsin Alumni Research Foundation Métodos para reducir la absorción de fosfato empleando un anticuerpo anti-Npt2B
CA2667613A1 (en) * 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption
MX2012006072A (es) * 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
JP7279026B2 (ja) 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
WO2020037225A1 (en) 2018-08-17 2020-02-20 Mersana Therapeutics, Inc. Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985604A (en) * 1997-02-24 1999-11-16 Incyte Pharmaceuticals, Inc. Human sodium-dependent phosphate cotransporter
US6319688B1 (en) * 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)

Also Published As

Publication number Publication date
US20020156266A1 (en) 2002-10-24
JP2003325189A (ja) 2003-11-18
ITMI20000200A0 (it) 2000-02-08
SE0000375L (sv) 2000-08-10
AU1497900A (en) 2000-08-31
JP2000245488A (ja) 2000-09-12
GB0002665D0 (en) 2000-03-29
US7368530B2 (en) 2008-05-06
FR2791348A1 (fr) 2000-09-29
US6380374B1 (en) 2002-04-30
US7803562B2 (en) 2010-09-28
BE1014389A5 (fr) 2003-10-07
GB2348645A (en) 2000-10-11
AT411759B (de) 2004-05-25
CA2296178A1 (en) 2000-08-09
ATA1972000A (de) 2003-10-15
CH694588A5 (de) 2005-04-15
NL1014331C2 (nl) 2003-06-03
CA2296178C (en) 2004-05-04
ITMI20000200A1 (it) 2001-08-08
DE10004815B4 (de) 2010-01-21
IE20000117A1 (en) 2000-09-06
DE10004815A1 (de) 2000-10-12
AU741170B2 (en) 2001-11-22
FR2791348B1 (fr) 2007-10-05
US20090170122A1 (en) 2009-07-02
NL1014331A1 (nl) 2000-08-10
SE0000375D0 (sv) 2000-02-07

Similar Documents

Publication Publication Date Title
US7803562B2 (en) Method for screening human intestinal Npt2B modulatory agents
JP2008522162A (ja) Ｍｅｒの診断用および治療用の作用薬
WO1999043696A1 (en) Human potassium channel genes
US20050221420A1 (en) Nogo receptor homologues and their use
JP2001517441A (ja) Ｇタンパク質共役糖タンパク質ホルモン受容体ｈｇ３８
US20100273256A1 (en) Human Potassium Channel Genes
US7141383B2 (en) EDG8 receptor, its preparation and use
EP1042471B1 (de) Säugertier edg-7 rezeptor homologen
WO2006068326A1 (ja) 新規ポリペプチドおよびその用途
US7314716B2 (en) Gustducin γ subunit materials and methods
US20090117590A1 (en) Human calcium sensitive potassium channel beta3 subunit proteins, encoding nucleic acid and uses thereof
KR100977824B1 (ko) Ｅｐｆ 수용체 에세이, 화합물 및 치료학적 조성물
WO2002094876A2 (en) Methods and compositions for treating respiratory mucin production associated disease conditions
WO1999038975A2 (en) Polynucleotide and polypeptide sequences associated with cns depressant sensitivity and methods of use thereof
US7312026B2 (en) MRP-related ABC transporter encoding nucleic acids and methods of use thereof
EP1227106A1 (de) Proapoptotische Proteine und dafür kodierende DNA Moleküle
US20070274988A1 (en) Kiaa0779, Splice Variants Thereof, and Methods of Their Use
WO2000049048A1 (en) Ndae1 - a new bicarbonate transporter
JP2003523181A (ja) Ｄｎａヘリカーゼ、ヒトｎｈｌをコードするｄｎａ分子
US20030105001A1 (en) Pro-apoptotic proteins and DNA molecules encoding them

Legal Events

Date Code Title Description
NUG Patent has lapsed